VASCEPA® (icosapent ethyl)—Elevating the Standard of Care
A Collaborative Discussion to Better Understand and Expedite the Patient Journey
Developed and offered by someone
Another line
We won't add links - this is only a test
H2
- HTML possible
- in excerpt
What’s New with GLP-1?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Enabling Telemedicine and Remote Monitoring With the Freestyle Libre 14 Day System (This Product Theater is Pre-Recorded)
Join us to learn about the #1 CGM worldwide† used by more than 2 million people*, the FreeStyleLibre 14-day system.Daniel Einhorn, MD, FACP, FACE, will share how he utilizes the FreeStyleLibre 14-day system to enable diabetes management and monitoring of patients remotely. Dr. Einhorn will also share real-world telemedicine patient cases.Presenter: Daniel Einhorn, MD, FACP, […]
Ethnic and Racial Disparities in Maternal, Perinatal, and Neonatal Mortality
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Doing Better for Diabetes and Chronic Kidney Disease (CKD)
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Transitions in Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Using Technologies to Track Physical Activity and Improve Health
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Adipose Innervation
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Which Diet Is Best for Treatment of Diabetes and Obesity?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
What’s New with Beta-Cell Replacement?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Functional Cure of Type 1 Diabetes—Where Shall We Take the Islet Cells From?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Tailoring Treatment Options Based on Diabetes Comorbidities
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Taking the Technology Plunge—Integrating Digital Technology into Practice
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Patients with Low Estimated Glomerular Filtration Rate
GEORGE BAKRIS, Chicago, IL
ADA Diabetes Care Symposium—Long-Term Perspectives on Study and Care of Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Culinary Medicine—Its Role in the Prevention and Treatment of Obesity, Diabetes, and Metabolic Syndrome
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Reduction of Hypoglycemia by New Therapies in Clinical Trials—Overestimated, Underestimated, or Both?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
ADA Education Recognition Program Symposium—Clinical Considerations for Safe, Cultural, Spiritual, and Therapeutic Fasting among People with Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Engaging the Immune System to Protect Beta Cells
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
The Impact of Environmental Temperature on Metabolic Regulation
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Thinking Beyond Glycemia—The Importance of Managing Heart Failure Risks in Type 2 Diabetes (This Product Theater is Pre-Recorded)
We will examine the risk of heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF risk reduction in patients with T2D […]
Are We Waiting Too Long to Start a GLP-1RA in Adult Patients with T2D? (For Non-U.S. HCPs Only) (This Product Theater is Pre-Recorded)
This presentation provides an overview of a GLP-1RA for adult patients with T2D, including an in-depth review of head-to-head data from the clinical trial program. The results from a CVOT will also be reviewed. Presenter: Adie Viljoen, MB, ChB, FCP, MD, FRCPath, MBAConsultant Metabolic PhysicianThe Lister HospitalStevenage, United Kingdom
Maximizing Long-Term Weight Loss Maintenance with Lifestyle Changes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
The New Physiology—Organs in a Dish—Promises, Pitfalls, and Potential Clinical Applications
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Clinical Management of Diabetic Neuropathies in 2020
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Slicing and Dicing—Prohormone Processing in Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Joint ADA/ISPAD Symposium—Hemoglobin A1C vs. Time-in-Range as the Primary Metric in Pediatric Diabetes?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?!
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Diabetes in Sub-Saharan Africa—Challenges and Opportunities
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Diabetes Devices and Digital Technologies—Who Does It Help the Most (and Least)? (With Richard R. Rubin Award Lecture)
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Chair
MICHAEL A. HARRIS, Portland, OR
Immunity, Metabolism, and Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Dilemmas in Diabetic Foot Infection Management
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Myosteatosis—What Happens When Skeletal Muscle Is Marbled Like Steak?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Chair
OSAMA HAMDY, Boston, MA
How Tech May Unintentionally Widen the Health Disparities Gap
LYNDSAY A. NELSON, Nashville, TN
Adjunctive Glucose-Lowering Therapies for Adults with Type 1 Diabetes—Evidence
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
The Islet under Duress in Type 1 Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Mind the Clock—Timing of Feeding in the Control of Metabolic Health
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Pancreas Transplantation—Why Aren’t We Doing More?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Lifestyle Interventions for Type 2 Diabetes Remission
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
ADA Diabetes Symposium—Unraveling the Heterogeneity in Type 2 Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
VASCEPA® (icosapent ethyl)—Elevating the Standard of Care (This Product Theater is Presented Live)
There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statin-based standard-of-care therapy in patients with elevated triglycerides. In this program, we will review data from a practice changing trial that provides a new therapeutic option to elevate the current standard of care.Presenter: Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE […]
Considerations for Glycemic Control—Choosing a Basal Insulin for Patients with Diabetes (This Product Theater is Pre-Recorded)
Presenter: Helen Baron, MD, CCDMedical Director, Diabetes ServicesEisenhower Diabetes and EndocrinologyEisenhower Medical AssociatesRancho Mirage, CA
New Insights from the Restoring Insulin Secretion (RISE) Study—Differences between Adults and Youth with Prediabetes and Type 2 Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Renal and Cardiovascular Outcomes in Adults with Diabetic Nephropathy (i.e., DKD) and Type 2 Diabetes (U.S. Only) (This Product Theater is Presented Live. It Will Not Be Available On Demand)
Topics include:•Renal and cardiovascular outcomes and overall safety profile in adults with diabetic nephropathy(i.e., diabetic kidney disease) and type 2 diabetes•Important Safety Information, followed by a question-and-answer sessionPresenter: Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACEEndocrinologistMedical Director & Principal InvestigatorMetabolic Institute of AmericaTarzana, CA
Understanding Chronic Kidney Disease in Type 2 Diabetes—The Risks, Recognition, and Clinical Management (This Product Theater is Presented Live. It Will Not Be Available On Demand)
Chronic Kidney Disease (CKD) develops in a substantial proportion of patients with type 2 diabetes (T2D) and significantly increases risk for adverse cardiovascular and renal outcomes. Multiple factors can contribute to the development and progression of CKD in T2D, although understanding of the etiology continues to evolve. The deleterious impact of CKD in T2D progresses […]
Break the Sequential T2DM Treatment Pattern in Adult Patients with High A1C (≥9%) on OADs, or Uncontrolled on GLP-1 Ras, and get them to Goal (This Product Theater is Pre-Recorded)
Presenter: Jeremy Pettus, MDAssistant Professor of MedicineDivision of EndocrinologyUniversity of California, San DiegoSan Diego, CA
Not Your Grandmother’s Transcription Factors—New Insights into Genomic Regulation of Beta-Cell Function
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Low-Carb Diets in Pediatric Type 1 Diabetes—Pros and Cons
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Joint ADA/Diabetes UK Symposium—Islet Transplantation—Quo Vadis?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Simplifying Diabetes Management—Advancing Innovation Across Outcomes, Patient Experience, and Support with the Guardian™ Connect Continuous Glucose Monitoring (CGM) System (U.S. Only) (This Product Theater is Pre-Recorded)
Please join us for a virtual product theater on Medtronic’s cutting-edge Guardian™ Connect continuous glucose monitoring (CGM) technology and the role it plays in virtual diabetes care. You will hear from Dr. Amit Bhargava, MD about real-world outcomes and case studies of patients using the Guardian™ Connect system with the Sugar.IQ™ diabetes assistant. This will […]
Physiological Mechanisms of Remission of Type 2 Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Menopause and Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
What Will Be the Impact of Proposed Health Policy Changes on Diabetes Care?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Joint ADA/ASN Symposium—Targeting Diabetic Kidney Disease (DKD)—Are We Ready for Precision Medicine Trials?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Nonalcoholic Steatohepatitis (NASH)—Emerging Concepts and Opportunities
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Population Health Efforts in the Prevention and Treatment of Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Joint ADA/EASD Symposium—Leveraging Metabolism to Prevent, Treat, or Cure Type 1 Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
From Genome-Wide Association Studies to Multiomics—Defining Diabetes Risk and Clinical Relevance
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Utilizing Diabetes Technology in the Real World—Tools of the Trade
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
How Do GLP-1 Receptor Agonists Provide Cardioprotection?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Trouble in the Neighborhood—Endocrine/Exocrine Interactions in Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Update from the TEDDY Study
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Multiomic Approaches in Explaining Diabetes Risk
PRAVEEN SETHUPATHY, Ithaca, NY
Disparities in Diabetes and Diabetes Care—What Can We Do about It?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Chinese Diabetes Society Symposium—Novel Antidiabetic Approaches and Potential Targets
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Artificial Intelligence (AI), Machine Learning, and Diabetes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Physical Activity and Diabetes—When, How Much, Insulin Adjustments, and More
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Fetal Sex and Pregnancy Outcomes
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Twenty Years of Pediatric Diabetes Surveillance—What Do We Know and Why It Matters—The SEARCH for Diabetes in Youth Study
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Weekly Basal Insulin—The Wave of the Future?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Novel Approaches for Cell and Tissue Interrogation—Using the Kidney as a Model
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Cognitive Function in Obesity and Appetite Regulation
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Lessons from Single Cell Genomics and Kidney Organoids
ANNA GREKA, Cambridge, MA
Diabetes Meets the Sandman—Sleep, Diabetes, and Glycemic Management
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Economic Drivers of Obesity Treatment—From Individuals to Systems
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
SGLT2 Inhibitors—How Do They Reduce Cardiorenal Disease?
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Immune Intervention During the Stages of Type 1 Diabetes Development—Type 1 Diabetes TrialNet
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.
Results of the eValuation of ERTugliflozin EffIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)
All sessions will be released on their scheduled date and time. The meeting is scheduled in U.S. Central Time. Registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.